Loading...
XNAS
SCNX
Market cap1mUSD
May 30, Last price  
0.87USD
1D
-3.51%
1Q
-67.01%
IPO
-88.15%
Name

TRxADE Health Inc

Chart & Performance

D1W1MN
P/E
0.17
P/S
11.20
EPS
5.18
Div Yield, %
171.57%
Shrs. gr., 5y
56.01%
Rev. gr., 5y
-55.04%
Revenues
137k
-98.35%
000806,047955,8811,496,2274,992,2032,481,8662,931,2803,831,7787,436,26417,122,5209,889,43311,448,2658,272,214136,643
Net income
9m
P
-8,725-28,186-28,497,000-150,713-2,091,285-2,012,043-1,117,183-2,760,125288,9839,038-409,730-2,565,440-4,113,047-4,310,205-17,843,5749,065,798
CFO
-14m
L+587.95%
-6,225-16,068-28,164,000-163,118-844,579-1,064,576-1,202,137-1,313,418171,670273,386141,775-2,214,786-2,566,226-1,525,929-2,073,601-14,265,238
Dividend
Jul 19, 20241.5 USD/sh
Earnings
Jun 24, 2025

Profile

TRxADE HEALTH, Inc. operates as a health services IT company in the United States. The company focuses on digitalizing the retail pharmacy experience by optimizing drug procurement, prescription journey, and patient engagement. It operates the TRxADE drug procurement marketplace, which fosters price transparency and serves approximately 11,800 members; and offers patient centric telehealth services under the Bonum Health brand name. The company was formerly known as Trxade Group, Inc. and changed its name to TRxADE HEALTH, Inc. in June 2021. TRxADE HEALTH, Inc. is based in Land O' Lakes, Florida.
URL
https://www.trxadehealth.com/
IPO date
Feb 18, 2020
Employees
33
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
137
-98.35%
8,272
-27.74%
11,448
15.76%
Cost of revenue
14,421
15,536
14,205
Unusual Expense (Income)
NOPBT
(14,285)
(7,263)
(2,757)
NOPBT Margin
Operating Taxes
(534)
5,336
400
Tax Rate
NOPAT
(13,750)
(12,599)
(3,157)
Net income
9,066
-150.81%
(17,844)
313.98%
(4,310)
4.79%
Dividends
(14,859)
Dividend yield
Proceeds from repurchase of equity
518
131
BB yield
Debt
Debt current
2,764
6,809
364
Long-term debt
989
1,392
2,304
Deferred revenue
Other long-term liabilities
3,582
(409)
Net debt
3,444
8,050
1,534
Cash flow
Cash from operating activities
(14,265)
(2,074)
(1,526)
CAPEX
(451)
Cash from investing activities
27,553
(276)
(428)
Cash from financing activities
(12,980)
1,406
(35)
FCF
(16,832)
(9,474)
(2,438)
Balance
Cash
308
152
1,134
Long term investments
Excess cash
301
561
Stockholders' equity
(39,039)
(33,246)
(20,140)
Invested Capital
125,225
40,211
22,066
ROIC
ROCE
EV
Common stock shares outstanding
3,654
2,381
565
Price
Market cap
EV
EBITDA
(14,231)
(6,214)
(2,561)
EV/EBITDA
Interest
1,336
1,198
336
Interest/NOPBT